The effect of ingaron on the dynamics of copies of deoxyribonucleic acid Epstein - Barr virus in saliva samples and on the manifestation of clinical

A total of 60 patients (38 women and 22 men, 36,54±2,14 years old) with a Epstein - Barr infection were examined. The patients were divided into two groups depending on the treatment regimen: 1 group - 34 patients received ingaron therapy (10 intramuscular injections of 500000 units every other day); group 2-26 patients received valcyte (450 mg 2 times a day, by mouth, 2 months) + ingaron at the same dosage. One month after the end of antiviral therapy in the1st group, negative results of half-chain reaction were obtained only in 29,41% of patients. The combination of valcyte and ingaron in patients of the 2nd group was different and differed in the duration of the injection of ingarone: 2a group: ingaron10 injections of 500000 IU intramuscularly every other day; 2b group: ingaron 20 injections of 500000 IU intramuscularly every other day; 2c group: ingaron 10 injections of 500000 IU and 15 injections of 100000 IU intramuscularly every other day. The best result after the introduction of ingaron was obtained in 90% of patients who received the longest course of ingaron in the form of 20 injections of 500000 IU every other day in combination with valcyte. In the other groups, where the total dose of ingaron was lower, positive results were found in 60 and 66,7% of patients. A significant positive change in the number of copies of deoxyribonucleic acid Epstein - Barr virus was found in samples of saliva and the severity of clinical complaints in patients one month after the ingaron monotherapy or combination therapy (valcyte and ingaron) was completed. The best effect of treatment with ingaron is achieved in patients with chronic Epstein - Barr infection with the prolonged introduction of ingaron (at least 20 injections).

Download Full-text

Cost-Effectiveness of Nasopharyngeal Carcinoma Screening with Epstein-Barr Virus Polymerase Chain Reaction or Serology in High-Incidence Populations Worldwide

JNCI Journal of the National Cancer Institute ◽

10.1093/jnci/djaa198 ◽

2020 ◽

Cited By ~ 1

Author(s):

Jacob A Miller ◽

Quynh-Thu Le ◽

Benjamin A Pinsky ◽

Hannah Wang

Keyword(s):

Cost Effectiveness ◽

Epstein Barr Virus ◽

Cost Effective ◽

Chain Reaction ◽

Men And Women ◽

Barr Virus ◽

Screening Strategies ◽

High Incidence ◽

Polymerase Chain ◽

Epstein Barr

Abstract Background The incidence of endemic Epstein-Barr Virus (EBV)-associated nasopharyngeal carcinoma (NPC) varies considerably worldwide. In high-incidence regions, screening trials have been conducted. We estimated the mortality reduction and cost-effectiveness of EBV-based NPC screening in populations worldwide. Methods We identified 380 populations in 132 countries with incident NPC and developed a decision-analytic model to compare ten unique onetime screening strategies to no screening for men and women at age 50 years. Screening performance and the stage distribution of undiagnosed NPC were derived from a systematic review of prospective screening trials. Results Screening was cost-effective in up to 14.5% of populations, depending on the screening strategy. These populations were limited to East Asia, Southeast Asia, North Africa, or were Asian, Pacific Islander, or Inuit populations in North America. A combination of serology and nasopharyngeal polymerase chain reaction (PCR) was most cost-effective, but other combinations of serologic and/or plasma PCR screening were also cost-effective. The estimated reduction in NPC mortality was similar across screening strategies. For a hypothetical cohort of patients in China, 10-year survival improved from 71.0% (95%CI = 68.8%–73.0%) without screening to a median of 86.3% (range = 83.5%–88.2%) with screening. This corresponded to a median 10-year reduction in NPC mortality of 52.9% (range= 43.1%–59.3%). Screening interval impacted absolute mortality reduction and cost-effectiveness. Conclusions We observed decreased NPC mortality with EBV-based screening. Screening was cost-effective in many high-incidence populations and could be extended to men and women as early as age 40 years in select regions. These findings may be useful when choosing among local public health initiatives.

Download Full-text